CC
KYMR icon

Commodore Capital’s Kymera Therapeutics KYMR Stock Holding History

Commodore Capital’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.7M Sell
250,000
-500,000
-67% -$43M 1.71% 18
2026
Q1 		$62.5M Hold
750,000
– – 3.61% 10
2025
Q4 		$58.4M Hold
750,000
– – 3.88% 11
2025
Q3 		$42.5M Hold
750,000
– – 2.07% 19
2025
Q2 		$32.7M Buy
+750,000
New +$25.8M 2.31% 17

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Commodore Capital's KYMR Position: Q2 2026 in Review

Commodore Capital reduced its Kymera Therapeutics (KYMR) stake by 67% in Q2 2026, selling an estimated $43M and leaving 250,000 shares worth $28.7M. The position accounts for 1.71% of the portfolio, ranked #18.

Commodore Capital first reported a position in KYMR in Q2 2025 and has held it in 5 quarters since. The position peaked at $62.5M in Q1 2026. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Commodore Capital held 250,000 shares of Kymera Therapeutics worth $28.7M as of Q2 2026.
  • Commodore Capital sold 500,000 Kymera Therapeutics shares in Q2 2026, an estimated $43M.
  • Kymera Therapeutics made up 1.71% of Commodore Capital's portfolio in Q2 2026, its #18 holding.
  • Commodore Capital first reported a position in Kymera Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Commodore Capital's Kymera Therapeutics position peaked at $62.5M in Q1 2026.
  • 276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Commodore Capital's 13F filing for Q2 2026, filed 14 Aug 2026.